Residency · Residency · Dermatology

Androgenetic Alopecia: Pathophysiology and Therapeutics

Introduction

Androgenetic alopecia (AGA) is the most common form of hair loss in both men and women, affecting approximately 50% of men by age 50 and 40% of women over their lifetime. It is a progressive, non-scarring alopecia characterized by follicular miniaturization driven by androgen activity in genetically predisposed individuals. While not medically dangerous, AGA significantly impacts self-esteem and quality of life, making it one of the most frequently addressed conditions in dermatology practice.

Pathophysiology

The Hair Cycle in AGA

The normal hair cycle consists of anagen (active growth, 2 to 7 years), catagen (regression, 2 to 3 weeks), and telogen (rest and shedding, 2 to 4 months). In AGA, the anagen phase is progressively shortened, leading to thinner, shorter hairs with each successive cycle. This process of follicular miniaturization transforms terminal hair follicles into vellus-like follicles that produce fine, short, unpigmented hairs. Eventually, the follicle may become so miniaturized that it produces no visible hair shaft.

Androgen Metabolism

Testosterone is converted to 5-alpha-dihydrotestosterone (DHT) by the enzyme 5-alpha-reductase (type I in sebaceous glands, type II in dermal papillae). DHT has approximately 5-fold greater affinity for the androgen receptor (AR) than testosterone. When DHT binds to the AR in genetically susceptible follicular dermal papilla cells, it activates genes that promote catagen entry and miniaturization. Key downstream signaling mediators include DKK-1 (a Wnt inhibitor), TGF-beta1, TGF-beta2, and IL-6, all of which are upregulated by DHT in AGA-susceptible follicles. A notable paradox exists: DHT promotes hair growth in the beard and body but causes miniaturization on the scalp, reflecting site-specific differences in dermal papilla cell gene expression.

Genetic Factors

AGA follows polygenic inheritance with variable penetrance. The androgen receptor gene (AR) on the X chromosome is the strongest identified risk locus, which explains the maternal inheritance pattern observed in some families. Genome-wide association studies have identified additional loci including 20p11 (near PAX1) and EDA2R. Both androgen-dependent and androgen-independent mechanisms contribute to the disease, particularly in female pattern hair loss.

Clinical Presentation

Male Pattern Hair Loss (MPHL)

Male pattern hair loss presents as progressive thinning in a characteristic pattern of bitemporal recession (receding hairline) followed by vertex (crown) thinning. The occipital scalp is preserved because these follicles lack androgen sensitivity, which forms the basis for hair transplant donor sites. The Hamilton-Norwood classification (types I through VII) provides the standard staging system. Onset may occur as early as puberty with significant progression by the 30s and 40s. Early-onset, severe MPHL may be associated with increased cardiovascular risk and metabolic syndrome.

Female Pattern Hair Loss (FPHL)

Female pattern hair loss presents as diffuse thinning of the crown and midline with preservation of the frontal hairline. The Ludwig classification (types I through III) describes progressive widening of the central part. The Christmas tree pattern (Olsen pattern) shows a widening triangular area of thinning with the base at the frontal hairline. Onset may occur at any age but is most common after menopause. Most women with FPHL have normal androgen levels, suggesting additional non-androgen pathogenic mechanisms. Evaluation for hyperandrogenism is warranted only if accompanied by signs such as hirsutism, acne, menstrual irregularity, or virilization.

<image>Clinical comparison showing Hamilton-Norwood classification stages III, V, and VII of male pattern hair loss alongside Ludwig classification stages I, II, and III of female pattern hair loss with characteristic distribution patterns</image>

Diagnosis

Clinical Assessment

The pattern distribution and preserved follicular ostia distinguish AGA from scarring alopecias. A positive hair pull test at the vertex with a negative pull test at the occiput supports the diagnosis. Signs of hyperandrogenism should be assessed in women.

Trichoscopy

The hallmark finding is hair diameter diversity (greater than 20% variability). Miniaturized hairs appear as thin, short, hypopigmented vellus hairs interspersed with terminal hairs. The peripilar sign (brown halo around follicular ostia) is an early finding indicating perifollicular inflammation. Yellow dots represent dilated, empty follicular infundibula filled with sebum and keratinous material. Single-hair follicular units predominate, replacing the normal 2 to 4 hairs per unit.

Laboratory Workup (Primarily for Women)

Laboratory evaluation includes ferritin (target greater than 40 ng/mL for hair health), TSH, and CBC. If hyperandrogenism is suspected, free and total testosterone, DHEA-S, prolactin, and 17-hydroxyprogesterone should be checked. SHBG and free androgen index may also be considered.

Scalp Biopsy

Scalp biopsy is rarely needed and is reserved for diagnostic uncertainty. Horizontal sections reveal a terminal-to-vellus hair ratio of less than 3:1 (compared to the normal 7:1), increased telogen count, and miniaturized follicles. No significant inflammation or scarring is present, which distinguishes AGA from other alopecias.

Treatment

First-Line Therapies

Topical Minoxidil

Topical minoxidil is FDA-approved for both men (5%) and women (2% and 5%) and is available as a solution or foam. Its mechanism involves potassium channel opening, which prolongs anagen, increases follicular size, and enhances perifollicular vascularity, though the exact mechanism is incompletely understood. It is applied to the dry scalp twice daily (solution) or once daily (5% foam). Visible improvement occurs at 3 to 6 months with peak effect at 12 months, and the medication must be continued indefinitely, as cessation leads to loss of regained hair within 3 to 6 months. Adverse effects include initial telogen shedding during the first 2 to 8 weeks (which patients should be reassured about), contact dermatitis (more common with the solution due to propylene glycol), and unwanted facial hypertrichosis. Oral minoxidil at low doses (1.25 to 5 mg daily) is increasingly used off-label with superior efficacy to topical formulations; monitoring for fluid retention, tachycardia, and pericardial effusion (rare at low doses) is appropriate.

Oral Finasteride (Men)

Finasteride is a 5-alpha-reductase type II inhibitor that reduces scalp DHT by approximately 70%. It is FDA-approved for MPHL at 1 mg daily, with superior efficacy at the vertex and moderate efficacy at the frontal hairline. Results are visible at 6 to 12 months with maximum benefit at 2 years. Adverse effects include sexual dysfunction (decreased libido, erectile dysfunction, decreased ejaculate volume) in 2 to 4% of patients, typically reversible upon discontinuation. Post-finasteride syndrome (persistent sexual and neuropsychiatric symptoms after discontinuation) is a controversial entity with conflicting epidemiologic data; patients should be counseled about reported risks. Finasteride is contraindicated in women of childbearing potential due to teratogenicity (risk of ambiguous genitalia in male fetuses), and women should not handle crushed tablets.

Oral Dutasteride

Dutasteride is a dual inhibitor of 5-alpha-reductase types I and II that reduces DHT by over 90%. Dosed at 0.5 mg daily, it is not FDA-approved for AGA but is widely used off-label. It may be more effective than finasteride, particularly in finasteride non-responders. Its longer half-life (5 weeks versus 6 to 8 hours for finasteride) is a distinguishing pharmacologic feature, and the same contraindications as finasteride apply.

Second-Line and Adjunctive Therapies

Spironolactone (100 to 200 mg daily, for women only) is an antiandrogen that blocks the AR and inhibits androgen synthesis, with potassium monitoring required and pregnancy contraindicated. Topical finasteride (0.25%) is an emerging option to minimize systemic exposure while maintaining scalp efficacy. Low-level laser therapy (LLLT) uses FDA-cleared devices that provide modest improvement through photobiomodulation, with mixed but generally favorable safety evidence. Platelet-rich plasma (PRP) is an autologous growth factor concentrate injected into the scalp with growing evidence of efficacy, though protocols are not standardized. Microneedling with a 1.0 to 1.5 mm dermaroller combined with topical minoxidil enhances penetration and may stimulate wound-healing growth factors.

Surgical Treatment

Hair transplantation is performed using either follicular unit transplantation (FUT, the strip method) or follicular unit extraction (FUE). Donor hairs from the androgen-resistant occipital scalp retain their characteristics when transplanted, a principle known as donor dominance. The best candidates have stable AGA with adequate donor density, and medical therapy should be optimized before and continued after transplantation. Realistic expectations are essential, as transplantation redistributes existing hair rather than creating new follicles.

<image>Diagram illustrating the mechanism of androgenetic alopecia showing testosterone conversion to DHT by 5-alpha reductase in the dermal papilla, DHT binding to androgen receptors, downstream signaling through DKK-1 and TGF-beta leading to follicular miniaturization, and the sites of action of finasteride and minoxidil</image>

Emerging Therapies

JAK inhibitors are under investigation and may address the inflammatory microenvironment in AGA. Wnt pathway activators target the Wnt/beta-catenin pathway to promote hair follicle neogenesis. Clascoterone (a topical antiandrogen FDA-approved for acne) is in trials for AGA. Stem cell and exosome therapies remain at the preclinical stage but hold potential for follicle regeneration.

Key Clinical Pearls

AGA is a clinical diagnosis in most cases, and biopsy is rarely required when trichoscopy shows classic miniaturization. Combination therapy (minoxidil plus finasteride or dutasteride) is more effective than monotherapy and should be the standard approach for moderate-to-severe MPHL. Women with FPHL and normal androgens can still benefit from antiandrogen therapy because androgen receptor sensitivity varies independently of serum levels. Low-dose oral minoxidil is gaining traction as a more convenient and effective alternative to topical application. Realistic expectations should be set: treatment slows progression and may partially reverse miniaturization but rarely restores full density.

<image>Before and after clinical photographs showing treatment response in male pattern hair loss after 12 months of combination finasteride and minoxidil therapy, with trichoscopy images demonstrating increased hair caliber and follicular unit density</image>

References

1. Olsen EA, Messenger AG, Shapiro J, et al. Evaluation and treatment of male and female pattern hair loss. J Am Acad Dermatol. 2005;52(2):301-311.
2. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.
3. Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Oral minoxidil for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2022;87(2):445-446.
4. Piraccini BM, Alessandrini A. Androgenetic alopecia. N Engl J Med. 2014;371(7):e10.

Read this lecture as Markdown